| Name | Destiny Pharma |
|---|---|
| Epic | DEST |
| Isin | GB00BDHSP575 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 3.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £2.87 | Debt ratio | n/a |
| Shares in issue | 95.51 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -144.96 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -9.3 | 52-week high / low | 2.40p / 82.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Destiny Pharma |
|---|---|
| Address | Unit 36 Sussex Innovation Centre, Science Park Square, Falmer, Brighton, United Kingdom, BN1 9SB |
| Telephone | +44 (0)1273 704 440 |
| Website | http://www.destinypharma.com/ |
| Director | Position |
|---|---|
| Mr Chris Tovey | CEO |
| Mr Nigel Brooksby | Non-Executive Director |
| Mrs Debra Barker | Non-Executive Director |
| Mr James Stearns | Non-Executive Director |
| Mr Aled Williams | Non-Executive Director |
| Sir Nigel Rudd | Non-Executive Chairman |
| Mr Shaun Claydon | CFO and Company Secretary |
| Dr William Love | Chief Scientific Officer |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 2.26 | 2.26 | 2.26 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 2.29 | 2.3 | 2.28 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 1.61 | 1.34 | 1.68 |
| Cash and equivalents | 4.9 | 4.65 | 9.74 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 8.8 | 8.28 | 13.7 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 1.17 | 0.77 | 1.27 |
| Long term liabilities | n/a | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 1.17 | 0.77 | 1.27 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 7.63 | 7.51 | 12.44 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 0.73 | 0.6 | 0.6 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -26.15 | -20.18 | -15.25 |
| Share premium account | 33.04 | 27.09 | 27.09 |
| Total equity | 7.63 | 7.51 | 12.44 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -7.4 | -6.02 | -6.55 |
| Pre-tax profit | -7.71 | -6.27 | -6.48 |